SEARCH

SEARCH BY CITATION

References

  • 1
    Lanes SF, Garcia Rodriguez LA, Huerta C. Respiratory medications and risk of asthma death. Thorax 2002; 57: 6836.
  • 2
    Van Staa TP, Leufkens HG, Abenhaim L et al. Use of oral corticosteroids in the United Kingdom. QJM 2000; 93: 10511.
  • 3
    Van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002; 13: 77787.
  • 4
    Kanis JA, Johansson H, Oden A et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004; 19: 8939.
  • 5
    Van Staa TP, Leufkens HG, Abenhaim L et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15: 9931000.
  • 6
    Van Staa TP, Leufkens HG, Abenhaim L et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000; 39: 13839.
  • 7
    Hubbard RB, Smith CJ, Smeeth L et al. Inhaled corticosteroids and hip fracture: a population-based case-control study. Am J Respir Crit Care Med 2002; 166: 15636.
  • 8
    Israel E, Banerjee TR, Fitzmaurice GM et al. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 2001; 345: 9417.
  • 9
    Suissa S, Baltzan M, Kremer R et al. Inhaled corticosteroid use and the risk of fracture. Am J Respir Crit Care Med 2003; 169: 838.
  • 10
    Van Staa TP, Leufkens HG, Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 2001; 16: 5818.
  • 11
    Martin RJ, Szefler SJ, Chinchilli VM et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med 2002; 165: 137783.
  • 12
    Van Staa TP, Leufkens HG, Cooper C. Inhaled corticosteroids and hip fracture: disease or drugs? Am J Respir Crit Care Med 2003; 168: 128; author reply 129.
  • 13
    Van Staa TP, Leufkens B, Cooper C. Bone loss and inhaled glucocorticoids. N Engl J Med 2002; 346: 5335.
  • 14
    Sin DD, Man JP, Man SF. The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am J Med 2003; 114: 104.
  • 15
    Lekamwasam S, Trivedi DP, Khaw KT. An association between respiratory function and bone mineral density in women from the general community: a cross sectional study. Osteoporos Int 2002; 13: 7105.
  • 16
    De Vries F, Van Staa TP, Bracke MS et al. Severity of obstructive airway disease and risk of osteoporotic fracture. Eur Respir J 2005; 25: 87984.
  • 17
    Herings RM. PHARMO: a Record Linkage System for Postmarketing Surveillance of Prescription Drugs in the Netherlands. the Netherlands: Utrecht University, 1993.
  • 18
    Heerdink ER, Leufkens HG, Herings RM et al. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med 1998; 158: 110812.
  • 19
    Herings RM, Stricker BH, De Boer A et al. Current use of thiazide diuretics and prevention of femur fractures. J Clin Epidemiol 1996; 49: 1159.
  • 20
    Anon. ATC Classification Index with DDDs 2002. Nydalen: WHO Collaborating Centre for Drug Statistics Methodology Norwegian Institute of Public Health, 2002.
  • 21
    Bourbeau J, Ernst P, Cockcoft D et al. Inhaled corticosteroids and hospitalisation due to exacerbation of COPD. Eur Respir J 2003; 22: 2869.
  • 22
    Spitzer WO, Suissa S, Ernst P et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326: 5016.
  • 23
    Van Ganse E, Van Der Linden PD, Leufkens HG et al. Asthma medications and disease exacerbations: an epidemiological study as a method for asthma surveillance. Eur Respir J 1995; 8: 185660.
  • 24
    Greenland S. Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology 1995; 6: 35665.
  • 25
    Richy F, Bousquet J, Ehrlich GE et al. Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review. Osteoporos Int 2003; 14: 17990.
  • 26
    Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with systemic and topical corticosteroids. J Intern Med 2005; 257: 37484.
  • 27
    Kanis JA, Borgstrom F, De Laet C et al. Assessment of fracture risk. Osteoporos Int 2005; 16: 5819.
  • 28
    Van Staa TP, Cooper C, Brusse LS et al. Inflammatory bowel disease and the risk of fracture. Gastroenterology 2003; 125: 15917.
  • 29
    Schee E vd, Dijk L v, Blom L et al. Consumentenpanel Gezondheidszorg peilt leemtes. Pharm Weekbl 2004; 139: 61822.
  • 30
    Cummings SR, Nevitt MC, Browner WS et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332: 76773.
  • 31
    Ionescu AA, Evans WD, Pettit RJ et al. Hidden depletion of fat-free mass and bone mineral density in adults with cystic fibrosis. Chest 2003; 124: 22208.
  • 32
    Kanis JA, Johnell O, Oden A et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int 2005; 16: 15562.
  • 33
    Wolff I, Van Croonenborg JJ, Kemper HC et al. The effect of exercise training programs on bone mass: a meta-analysis of published controlled trials in pre- and postmenopausal women. Osteoporos Int 1999; 9: 112.
  • 34
    Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 2000; 18: 157093.